UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Baricitinib for COVID-19: a suitable treatment?

The Lancet infectious diseases, 2020-09, Vol.20 (9), p.1012-1013

2020

Volltextzugriff (PDF)

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis

Rheumatology and therapy., 2020-09, Vol.7 (3), p.473-516

Favalli, Ennio G.

2020

Volltextzugriff (PDF)

Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review

Arthritis care & research (2010), 2024-08

2024

Volltextzugriff (PDF)

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Seminars in arthritis and rheumatism, 2017-10, Vol.47 (2), p.183-192

2017

Volltextzugriff (PDF)

Secukinumab in HLA‐B27 associated uveitis

Clinical & experimental ophthalmology, 2021-05, Vol.49 (4), p.388-389

2021

Volltextzugriff (PDF)

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review

Therapeutic Advances in Musculoskeletal Disease, 2020, Vol.12, p.1759720X20906040-1759720X20906040

2020

Volltextzugriff (PDF)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection

Drug design, development and therapy, 2019-01, Vol.13, p.57-70

2019

Volltextzugriff (PDF)

Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an “anchor” drug?

Autoimmunity reviews, 2014-11, Vol.13 (11), p.1102-1108

2014

Volltextzugriff (PDF)

Potential Short-Term Air Pollution Effects on Rheumatoid Arthritis Activity in Metropolitan Areas in the North of Italy: A Cross-Sectional Study

International journal of environmental research and public health, 2021-08, Vol.18 (16), p.8490

2021

Volltextzugriff (PDF)

Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine

Arthritis research & therapy, 2022-01, Vol.24 (1), p.21-8, Article 21

2022

Volltextzugriff (PDF)

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Arthritis care & research (2010), 2022-07, Vol.74 (7), p.1205-1218

2022

Volltextzugriff (PDF)

Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients

Arthritis research & therapy, 2024-09, Vol.26 (1), p.161-12, Article 161

2024

Volltextzugriff (PDF)

Damage progression in rheumatoid arthritis: the role of biologic agents

Arthritis research & therapy, 2012-01, Vol.14 (S2), p.A9-A9, Article A9

Favalli, Ennio Giulio

2012

Volltextzugriff (PDF)

Biomarkers in psoriatic arthritis: a systematic literature review

Expert review of clinical immunology, 2016-06, Vol.12 (6), p.651-660

2016

Volltextzugriff (PDF)

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

Seminars in arthritis and rheumatism, 2016-04, Vol.45 (5), p.519-532

2016

Volltextzugriff (PDF)

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry

Clinical and experimental rheumatology, 2017-09, Vol.35 (5), p.804

2017

Volltextzugriff (PDF)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

Drug design, development and therapy, 2017-01, Vol.11, p.1593-1603

2017

Volltextzugriff (PDF)

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

Arthritis research & therapy, 2020-12, Vol.22 (1), p.290-12, Article 290

2020

Volltextzugriff (PDF)

Twelve‐Year Retention Rate of First‐Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real‐Life Data From a Local Registry

Arthritis care & research (2010), 2016-04, Vol.68 (4), p.432-439

2016

Volltextzugriff (PDF)

Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA

Joint, bone, spine : revue du rhumatisme, 2021-01, Vol.88 (1), p.105062-105062, Article 105062

2021

Volltextzugriff (PDF)

Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry

International journal of rheumatic diseases, 2018-02, Vol.21 (2), p.422-430

2018

Volltextzugriff (PDF)

Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis

Journal of rheumatology, 2020-08, Vol.47 (8), p.1296-1296

2020

Volltextzugriff (PDF)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Drugs in Context, 2019-10, Vol.8, p.1-12

2019

Volltextzugriff (PDF)

COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country

Pediatric rheumatology online journal, 2020-04, Vol.18 (1), p.35-7, Article 35

2020

Volltextzugriff (PDF)

Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort

Rheumatology international, 2020-02, Vol.40 (2), p.263-272

2020

Volltextzugriff (PDF)

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(144)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(151)

Sprache

Englisch
(149)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(123)
Life Sciences & Biomedicine
(122)
Humans
(88)
Rheumatoid Arthritis
(76)
Rheumatology
(73)
Arthritis, Rheumatoid - Drug Therapy
(53)
Antirheumatic Agents - Therapeutic Use
(48)
Male
(48)
Female
(47)
Middle Aged
(45)
Aged
(36)
Arthritis
(34)
Adult
(33)
Immunology
(31)
Monoclonal Antibodies
(25)
Treatment Outcome
(24)
Patients
(23)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(23)
Etanercept
(22)
Italy
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Baricitinib for COVID-19: a suitable treatment?

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis

Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Secukinumab in HLA‐B27 associated uveitis

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection

Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an “anchor” drug?

Potential Short-Term Air Pollution Effects on Rheumatoid Arthritis Activity in Metropolitan Areas in the North of Italy: A Cross-Sectional Study

Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients

Damage progression in rheumatoid arthritis: the role of biologic agents

Biomarkers in psoriatic arthritis: a systematic literature review

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

Twelve‐Year Retention Rate of First‐Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real‐Life Data From a Local Registry

Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA

Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry

Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country

Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort

Suchergebnisse filtern